目的通过Meta分析评估高压氧疗法对急性脑梗死的有效性和安全性。方法在PubMed、Web of Science、EMBASE、the Cochrane Library、维普、万方和中国知网等数据库中检索2000年1月1日—2023年6月30日发表的高压氧治疗急性脑梗死的随机对...目的通过Meta分析评估高压氧疗法对急性脑梗死的有效性和安全性。方法在PubMed、Web of Science、EMBASE、the Cochrane Library、维普、万方和中国知网等数据库中检索2000年1月1日—2023年6月30日发表的高压氧治疗急性脑梗死的随机对照试验(RCT),根据纳排标准进行文献筛选并提取数据,使用RevMan 5.4软件进行Meta分析。结果共纳入20篇RCT,Meta分析显示,高压氧联合常规西医内科治疗组急性脑梗死病人的总有效率高于常规西医内科治疗组,治疗后美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数评分和血管内皮生长因子(VEGF)水平均优于常规西医内科治疗组(P<0.05)。结论与常规的西医内科疗法相比,高压氧联合疗法治疗急性脑梗死在提高总有效率、NIHSS评分、Barthel指数评分、VEGF水平方面有效性更高。展开更多
An integrity monitoring framework is proposed to ensure the quality of the real-time Precise Point Positioning(PPP)correction data at the service end.The key contributions are designing quantitative metrics to charact...An integrity monitoring framework is proposed to ensure the quality of the real-time Precise Point Positioning(PPP)correction data at the service end.The key contributions are designing quantitative metrics to characterize the integrity status of the precise Orbit,Clock(OC)and Code Bias(OCB)corrections,and deriving the corresponding algorithms to detect and exclude anomalies,and to evaluate the real-time accuracy levels of the OCB.Compared to many prior works whose interests focused on analyzing and improving the averaged long-term accuracy,this work is established from integrity perspective.In particular,a two-layer fault detection and identification approach is developed to reduce the miss detection and false alert probabilities.The test statistics are constructed based on the raw observations from a network of worldwide sparsely distributed monitor stations.In addition,a realistic data-driven model is established to compute the Quality Indicators(QI)for healthy OCB products.The proposed scheme is validated respectively for multi-constellation OC and code bias,using historical correction data.The results suggest that the detection algorithms can effectively identify and alert the faults,so that the remaining correction errors approximate well to Gaussian distributions.Moreover,the computed QI are shown to be consistent with the truth error variations in real time.Most importantly,the position domain verification shows noticeable positioning accuracy and robustness improvements under both nominal and faulty conditions of the OCB correction data.展开更多
目的探讨司美格鲁肽联合二甲双胍治疗肥胖/超重2型糖尿病(OB/OW-T2DM)的效果,同时分析其对血糖控制达标率、胰岛素抵抗、体脂参数的影响。方法纳入2022年6月至2024年10月宁德师范学院附属宁德市医院收治的OB/OWT2DM患者,根据是否加用司...目的探讨司美格鲁肽联合二甲双胍治疗肥胖/超重2型糖尿病(OB/OW-T2DM)的效果,同时分析其对血糖控制达标率、胰岛素抵抗、体脂参数的影响。方法纳入2022年6月至2024年10月宁德师范学院附属宁德市医院收治的OB/OWT2DM患者,根据是否加用司美格鲁肽治疗,将其分为联合用药组(采用司美格鲁肽联合二甲双胍治疗)和二甲双胍组(采用二甲双胍治疗),经倾向性匹配评分法排除基线资料混杂因素影响,每组各获得135例基线资料可比患者。持续治疗3个月,对比两组临床疗效、血糖控制达标率[空腹血糖(FPG)达标率、糖化血红蛋白(HbA1c)达标率、两者均达标率],治疗前后血糖代谢水平[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、胰岛素抵抗相关指标[脂联素(APN)、瘦素(LEP)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)]水平、体脂参数水平[身体质量指数(BMI)、腰臀比(WHR)、体脂率],并统计不良反应发生率。结果用药3个月后,联合用药组总有效率(94.07%)(127/135)高于二甲双胍组(86.67%)(117/135),差异有统计学意义(χ^(2)=4.256,P<0.05);联合用药组FPG达标率(82.96%)(112/135)、HbA1c达标率(78.52%)(106/135)及两者均达标率(61.48%)(83/135)均高于二甲双胍组[(72.59%)(98/135)、(67.41%)(91/135)、(40.00%)(54/135)],差异有统计学意义(χ^(2)=4.200,4.224,12.462,P<0.05);联合用药组和二甲双胍组的FPG、2 h PG及HbA1c水平[分别为(6.79±1.19)mmol·L^(-1)、(7.61±1.23)mmol·L^(-1),(8.12±1.21)mmol·L^(-1)、(9.31±1.36)mmol·L^(-1),(6.76±1.01)%、(7.58±1.13)%]均低于用药前[分别为(9.35±1.61)mmol·L^(-1)、(9.26±1.43)mmol·L^(-1),(12.76±2.25)mmol·L^(-1)、(12.69±2.21)mmol·L^(-1),(8.51±0.71)%、(8.62±0.79)%],且联合用药组低于二甲双胍组,差异有统计学意义(t=5.567,7.596,6.286,P<0.05);联合用药组和二甲双胍组的APN和HOMA-β水平[分别为(7.53±1.42)mg·L^(-1)、(6.55±1.23)mg·L^(-1),(66.73±5.61)、(61.72±5.01)]均高于用药前[分别为(5.21±1.02)mg·L^(-1)、(5.16±1.01)mg·L^(-1),(41.84±3.57)、(41.68±3.55)],且联合用药组高于二甲双胍组,差异有统计学意义(t=6.061,7.739,P<0.05);联合用药组和二甲双胍组的LEP、FINS和HOMA-IR水平[分别为(18.23±1.87)ng·mL^(-1)、(20.34±2.09)ng·mL^(-1),(12.25±1.57)mIU·L^(-1)、(13.82±1.77)mIU·L^(-1),(2.54±0.49)、(3.25±0.63)]均低于用药前[分别为(22.44±2.32)ng·mL^(-1)、(22.65±2.33)ng·mL^(-1),(18.63±1.86)mIU·L^(-1)、(18.59±2.13)mIU·L^(-1),(4.23±0.82)、(4.26±0.84)],且联合用药组低于二甲双胍组,差异有统计学意义(t=8.742,7.710,7.195,P<0.05);联合用药组和二甲双胍组的BMI、WHR及体脂率水平[分别为(26.28±1.48)kg·(m^(2))^(-1)、(27.53±1.89)kg·(m^(2))^(-1),(0.88±0.06)、(0.92±0.03),(30.35±1.81)%、(31.83±1.93)%]均低于用药前[分别为(29.25±2.51)kg·(m^(2))^(-1)、(29.32±2.42)kg·(m^(2))^(-1),(0.96±0.08)、(0.95±0.09),(34.24±2.01)%、(34.35±2.07)%],且联合用药组低于二甲双胍组,差异有统计学意义(t=6.050,6.928,6.499,P<0.05);两组不良反应发生率[分别为10.37%(14/135)、6.67%(9/135)]差异无统计学意义(χ^(2)=1.188,P>0.05)。结论司美格鲁肽联合二甲双胍治疗OB/OW-T2DM疗效显著,能显著改善血糖控制达标率、血糖代谢水平、胰岛素抵抗相关指标和体脂参数水平,且安全性良好。展开更多
基金supported by supported by the National Key Research and Development Plan,China(No.2023YFB3906501)the National Natural Science Foundation of China(No.42227802)the Fundamental Research Funds for the Central Universities,China(No.501JCGG2024133001)。
文摘An integrity monitoring framework is proposed to ensure the quality of the real-time Precise Point Positioning(PPP)correction data at the service end.The key contributions are designing quantitative metrics to characterize the integrity status of the precise Orbit,Clock(OC)and Code Bias(OCB)corrections,and deriving the corresponding algorithms to detect and exclude anomalies,and to evaluate the real-time accuracy levels of the OCB.Compared to many prior works whose interests focused on analyzing and improving the averaged long-term accuracy,this work is established from integrity perspective.In particular,a two-layer fault detection and identification approach is developed to reduce the miss detection and false alert probabilities.The test statistics are constructed based on the raw observations from a network of worldwide sparsely distributed monitor stations.In addition,a realistic data-driven model is established to compute the Quality Indicators(QI)for healthy OCB products.The proposed scheme is validated respectively for multi-constellation OC and code bias,using historical correction data.The results suggest that the detection algorithms can effectively identify and alert the faults,so that the remaining correction errors approximate well to Gaussian distributions.Moreover,the computed QI are shown to be consistent with the truth error variations in real time.Most importantly,the position domain verification shows noticeable positioning accuracy and robustness improvements under both nominal and faulty conditions of the OCB correction data.
文摘目的探讨司美格鲁肽联合二甲双胍治疗肥胖/超重2型糖尿病(OB/OW-T2DM)的效果,同时分析其对血糖控制达标率、胰岛素抵抗、体脂参数的影响。方法纳入2022年6月至2024年10月宁德师范学院附属宁德市医院收治的OB/OWT2DM患者,根据是否加用司美格鲁肽治疗,将其分为联合用药组(采用司美格鲁肽联合二甲双胍治疗)和二甲双胍组(采用二甲双胍治疗),经倾向性匹配评分法排除基线资料混杂因素影响,每组各获得135例基线资料可比患者。持续治疗3个月,对比两组临床疗效、血糖控制达标率[空腹血糖(FPG)达标率、糖化血红蛋白(HbA1c)达标率、两者均达标率],治疗前后血糖代谢水平[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、胰岛素抵抗相关指标[脂联素(APN)、瘦素(LEP)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)]水平、体脂参数水平[身体质量指数(BMI)、腰臀比(WHR)、体脂率],并统计不良反应发生率。结果用药3个月后,联合用药组总有效率(94.07%)(127/135)高于二甲双胍组(86.67%)(117/135),差异有统计学意义(χ^(2)=4.256,P<0.05);联合用药组FPG达标率(82.96%)(112/135)、HbA1c达标率(78.52%)(106/135)及两者均达标率(61.48%)(83/135)均高于二甲双胍组[(72.59%)(98/135)、(67.41%)(91/135)、(40.00%)(54/135)],差异有统计学意义(χ^(2)=4.200,4.224,12.462,P<0.05);联合用药组和二甲双胍组的FPG、2 h PG及HbA1c水平[分别为(6.79±1.19)mmol·L^(-1)、(7.61±1.23)mmol·L^(-1),(8.12±1.21)mmol·L^(-1)、(9.31±1.36)mmol·L^(-1),(6.76±1.01)%、(7.58±1.13)%]均低于用药前[分别为(9.35±1.61)mmol·L^(-1)、(9.26±1.43)mmol·L^(-1),(12.76±2.25)mmol·L^(-1)、(12.69±2.21)mmol·L^(-1),(8.51±0.71)%、(8.62±0.79)%],且联合用药组低于二甲双胍组,差异有统计学意义(t=5.567,7.596,6.286,P<0.05);联合用药组和二甲双胍组的APN和HOMA-β水平[分别为(7.53±1.42)mg·L^(-1)、(6.55±1.23)mg·L^(-1),(66.73±5.61)、(61.72±5.01)]均高于用药前[分别为(5.21±1.02)mg·L^(-1)、(5.16±1.01)mg·L^(-1),(41.84±3.57)、(41.68±3.55)],且联合用药组高于二甲双胍组,差异有统计学意义(t=6.061,7.739,P<0.05);联合用药组和二甲双胍组的LEP、FINS和HOMA-IR水平[分别为(18.23±1.87)ng·mL^(-1)、(20.34±2.09)ng·mL^(-1),(12.25±1.57)mIU·L^(-1)、(13.82±1.77)mIU·L^(-1),(2.54±0.49)、(3.25±0.63)]均低于用药前[分别为(22.44±2.32)ng·mL^(-1)、(22.65±2.33)ng·mL^(-1),(18.63±1.86)mIU·L^(-1)、(18.59±2.13)mIU·L^(-1),(4.23±0.82)、(4.26±0.84)],且联合用药组低于二甲双胍组,差异有统计学意义(t=8.742,7.710,7.195,P<0.05);联合用药组和二甲双胍组的BMI、WHR及体脂率水平[分别为(26.28±1.48)kg·(m^(2))^(-1)、(27.53±1.89)kg·(m^(2))^(-1),(0.88±0.06)、(0.92±0.03),(30.35±1.81)%、(31.83±1.93)%]均低于用药前[分别为(29.25±2.51)kg·(m^(2))^(-1)、(29.32±2.42)kg·(m^(2))^(-1),(0.96±0.08)、(0.95±0.09),(34.24±2.01)%、(34.35±2.07)%],且联合用药组低于二甲双胍组,差异有统计学意义(t=6.050,6.928,6.499,P<0.05);两组不良反应发生率[分别为10.37%(14/135)、6.67%(9/135)]差异无统计学意义(χ^(2)=1.188,P>0.05)。结论司美格鲁肽联合二甲双胍治疗OB/OW-T2DM疗效显著,能显著改善血糖控制达标率、血糖代谢水平、胰岛素抵抗相关指标和体脂参数水平,且安全性良好。
